Cargando…

Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?

In the past decade, immune checkpoint inhibitor (ICI) therapy significantly improved the prognosis of patients with cancer. Despite impressive and often unprecedented response rates, a significant portion of the patients fails to benefit from this treatment. Additional strategies to improve ICI effi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vos, Winnie G, Lutgens, Esther, Seijkens, Tom T P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Hypothesis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442479/ http://dx.doi.org/10.1136/jitc-2022-005611

Ejemplares similares

Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease
por: Lutgens, Esther, et al.
Publicado: (2020)

Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem
por: Poels, Kikkie, et al.
Publicado: (2021)

E3 Ubiquitin Ligases as Immunotherapeutic Target in Atherosclerotic Cardiovascular Disease
por: Poels, Kikkie, et al.
Publicado: (2020)

Hypothesis: does adrenalitis caused by immune checkpoint-inhibitors put melanoma patients at an elevated risk for recurrence?
por: Harsch, Igor Alexander
Publicado: (2019)

T follicular helper cells: linking cancer immunotherapy and immune-related adverse events
por: Baumjohann, Dirk, et al.
Publicado: (2021)

Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups
por: Hsiehchen, David, et al.
Publicado: (2021)

Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade
por: Zheng, Ming
Publicado: (2022)

Evolutionary analysis of WD40 super family proteins involved in spindle checkpoint and RNA export: Molecular evolution of spindle checkpoint
por: Reddy, Duvvuru muni Rajasekhara, et al.
Publicado: (2008)

C-Type Lectin Receptors-Triggered Antifungal Immunity May Synergize with and Optimize the Effects of Immunotherapy in Hepatocellular Carcinoma
por: Xia, Jinkun, et al.
Publicado: (2023)

The role of monocyte phenotype switching in peri-procedural myocardial injury and its involvement in statin therapy
por: Yang, Yang, et al.
Publicado: (2013)

Mitochondrial Genetic Background May Impact Statins Side Effects and Atherosclerosis Development in Familial Hypercholesterolemia
por: Ruiz-Pesini, Eduardo, et al.
Publicado: (2022)

Microbiome-derived metabolome as a potential predictor of response to cancer immunotherapy
por: Malczewski, Agnieszka Beata, et al.
Publicado: (2020)

Rethinking the immunotherapy numbers game
por: Bekker, Rebecca A, et al.
Publicado: (2022)

The G2 checkpoint—a node‐based molecular switch
por: de Gooijer, Mark C., et al.
Publicado: (2017)

Molecular docking based screening of Listeriolysin-O for improved inhibitors
por: Ghafari, Sara, et al.
Publicado: (2017)

Important genetic checkpoints for insulin resistance in salt-sensitive (S) Dahl rats
por: Shehata, Marlene F
Publicado: (2008)

The Interleukin-6 inflammation pathway from cholesterol to aging – Role of statins, bisphosphonates and plant polyphenols in aging and age-related diseases
por: Omoigui, Sota
Publicado: (2007)

Selection of an improved HDAC8 inhibitor through structure-based drug design
por: Vijayakumar, Balakrishnan, et al.
Publicado: (2011)

JAK Inhibitors as Potential Therapeutic Strategy for the Dilemma of Psoriasis Concurrent with Dermatomyositis in the SARS-CoV-2 Era
por: Xu, Qiannan, et al.
Publicado: (2023)

Strengthening the Brain—Is Resistance Training with Blood Flow Restriction an Effective Strategy for Cognitive Improvement?
por: Törpel, Alexander, et al.
Publicado: (2018)

Cancer immunotherapy beyond immune checkpoint inhibitors
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Comparative modeling of CCRL1, a key protein in masked immune diseases and virtual screening for finding inhibitor of this protein
por: Behjati, Mohaddeseh, et al.
Publicado: (2012)

The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy
por: Mpakali, Anastasia, et al.
Publicado: (2021)

Modeling survival in colon cancer: a methodological review
por: Ahmed, Farid E, et al.
Publicado: (2007)

Establishing Imaging Biomarkers of Host Immune System Efficacy during Glioblastoma Therapy Response: Challenges, Obstacles and Future Perspectives
por: Candiota, Ana Paula, et al.
Publicado: (2022)

Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer
por: van Holstein, Yara, et al.
Publicado: (2019)

Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies
por: Rodriguez-Pascual, Jesus, et al.
Publicado: (2019)

Autophagy as a novel strategy for treatment of gastric cancer: A hypothesis
por: Liu, Donglei, et al.
Publicado: (2013)

Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?
por: Constantinescu, Catalin, et al.
Publicado: (2020)

Not all hematopoietic growth factors are created equal: should we gain information for their use with immunotherapy?
por: Bossi, Paolo, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor Therapy Aggravates T Cell–Driven Plaque Inflammation in Atherosclerosis
por: Poels, Kikkie, et al.
Publicado: (2020)

Computer aided screening of inhibitors to 5-α reductase type 2 for prostate cancer
por: Bhattacharjee, Biplab, et al.
Publicado: (2011)

Molecular docking analysis of known flavonoids as duel COX-2 inhibitors in the context of cancer
por: Dash, Raju, et al.
Publicado: (2015)

Efficacy and safety of oral immunotherapy for peanut allergy: a pilot study in Singaporean children
por: Zhong, Youjia, et al.
Publicado: (2018)

New strategy for antimetastatic treatment of lung cancer: a hypothesis based on circulating tumour cells
por: Que, Zujun, et al.
Publicado: (2022)

Screening of inhibitors for S130G inhibitor resistant mutants of TEM type beta-lactamase
por: Baig, Mohd Hassan, et al.
Publicado: (2012)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
por: Bai, Rilan, et al.
Publicado: (2020)

Immune oncology, immune responsiveness and the theory of everything
por: Turan, Tolga, et al.
Publicado: (2018)

Identifications small molecules inhibitor of p53-mortalin complex for cancer drug using virtual screening
por: Utomo, Didik H, et al.
Publicado: (2012)

Do the benefits of being a smoker hint at the existence of PD-1/PD-L1 sensitizers for patients on single-agent immunotherapy?
por: Zaleskis, Gintaras, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_24dv02ij518v3lr5nrvq46n524